Drug Trial Radar · NCT02610348
Anti-Hep B Antibodies at Age 12 to 18 Months After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine Concomitantly With Prevnar® at 2, 4 and 6 Months of Age
Last checked: Nov 19, 2026Latest source record: Mar 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
122
Actual
Start
Nov 2015
Primary completion
Dec 2015
Study completion Mar 2016
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 20, 2015
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- Who can join
- All sexes, from 12 months, up to 18 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Primary Objective: To describe the persistence of Hep B antibodies (Ab) at 12 to 18 months of age following a three-dose infant primary series vaccination of either Hexaxim®/Hexyon®/Hexacima® or Infanrix® hexa at 2, 4 and 6 months of age following Hep B vaccination at birth.
Conditions
- Hepatitis B
Interventions
DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccinesBiological
Original Vaccine in Study A3L12 (NCT00401531). No vaccination will be administered as part of this study
DTaP-HB-IPV and Pneumococcal polysaccharide vaccinesBiological
Original Vaccine in Study A3L12 (NCT00401531). No vaccination will be administered as part of this study
Primary outcomes
What the sponsor says the trial is designed to measure.
- Levels of anti-Hepatitis B antibody concentrations in subject that received Hexaxim® or Infanrix® hexa vaccine in a previous studyTime frame: Day 0
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Bangkok, Thailand
Site not named
Khon Kaen, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.